Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era.
Catania C, Piperno G, Russo A, Greco C, Agustoni F, Scotti V, Proto C, Sangalli C, Patani F, Santacaterina A, Di Pietro Paolo M, Agresti B, Filippi AR, Ramella S.
Catania C, et al. Among authors: ramella s.
Crit Rev Oncol Hematol. 2022 Jun;174:103684. doi: 10.1016/j.critrevonc.2022.103684. Epub 2022 Apr 21.
Crit Rev Oncol Hematol. 2022.
PMID: 35462031
Review.